Our study represents a first step in understanding the possibilities of the MSC approach to treatment of alkali injuries of the cornea and shows that such an approach improves clinical outcomes and leads to better prognosis.

Preliminary data of four pediatric patients with moderate keratoconus show feasibility of treatment by CXL in these select patients with no intra- or postoperative complications over 3-year follow-up.

After riboflavin-UVA CXL in eyes with keratoconus, there was a significant increase in IOP measured by GAT that was probably caused by an increase in corneal rigidity.

In order to test the validity of contrast sensitivity (CS) measurements in the early detection of visual impairment in age-related macular degeneration (AMD), we have evaluated the findings of CS in patients with drusen and normal visual acuity (17 eyes), as well as in the contralateral ‘healthy’ eye of patients with AMD (14 eyes). We also tried to estimate the validity of CS measurements in the prognosis of neovascular macular degeneration. The CS findings were evaluated in comparison to the findings of CS measurements in age-matched controls (32 eyes). CS loss is a constant finding in eyes with drusen and normal visual acuity. CS loss is more important at the middle range and high spatial frequencies. CS loss and degree of CS loss are not prognostic indicators of neovascular macular degeneration.

The 2-minute test is more acceptable by both the examiners and the examined individuals and may be used, in respect to the above results, as an alternative of the 5-minute test. Normal individuals tend to have Schirmer test I values > or = 10 mm in 2 minutes, irrespective of age and gender.